Nicotine / trötthet

Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, Alzheimer'S disease, sleep disorders, Parkinson'S disease, AIDS, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The present invention relates to transdermal devices and methods for controllable dispensing of a nutraceutical or an active substance such as a chemical substance, a medication, a drug, a stimulant or the like, to a human or other mammal for purposes of promoting longevity,

Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The present invention relates to transdermal devices and methods for controllable dispensing of a nutraceutical or an active substance such as a chemical substance, a medication, a drug, a stimulant or the like, to a human or other mammal for purposes of promoting longevity,

Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The present invention relates to transdermal devices and methods for controllable dispensing of a nutraceutical or an active substance such as a chemical substance, a medication, a drug, a stimulant or the like, to a human or other mammal for purposes of promoting longevity,

Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The present invention relates to transdermal devices and methods for controllable dispensing of a nutraceutical or an active substance such as a chemical substance, a medication, a drug, a stimulant or the like, to a human or other mammal for purposes of promoting longevity,

Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION The present invention relates to transdermal devices and methods for controllable dispensing of a nutraceutical or an active substance such as a chemical substance, a medication, a drug, a stimulant or the like, to a human or other mammal for purposes of promoting longevity,

Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (+)-bupropion

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

1. FIELD OF THE INVENTION This invention relates to methods and pharmaceutical compositions for aiding smoking cessation, treating nicotine addiction, and pain, including chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders. 2. BACKGROUND OF THE INVENTION Many

Methods and compositions for treating chronic disorders using optically pure (+)-bupropion

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

FIELD OF THE INVENTION This invention relates to methods and pharmaceutical compositions for aiding smoking cessation, treating nicotine addiction, and pain, including chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders. BACKGROUND OF THE INVENTION Many organic

Pharmaceutically active morpholinol

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

This invention relates to an optically pure morpholinol, salts and solvates thereof, pharmaceutical formulations containing them and processes for their preparation and use. BACKGROUND OF THE INVENTION Bupropion hydrochloride, (.+-.)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)-amino]-1-propanone

2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the

2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the

2-halo-5-alkynyl-pyridyl nicotinic ligands

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated cation channels in the central nervous system (CNS) and the peripheral nervous system (PNS). The nAChRs serve a wide range of physiological functions, and have been implicated in a number of pathological

2-halo-5-alkynyl-pyridyl nicotinic ligands

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated cation channels in the central nervous system (CNS) and the peripheral nervous system (PNS). The nAChRs serve a wide range of physiological functions, and have been implicated in a number of pathological

Phenyl-substituted nicotinic ligands, and methods of use thereof

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the

Phenyl-substituted nicotinic ligands, and methods of use thereof

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the

Ligands for nicotinic acetylcholine receptors, and methods of making and using them

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND OF THE INVENTION The endogenous cholinergic neurotransmitter, acetylcholine, exert its biological effect via two types of cholinergic receptors; the muscarinic ACh receptors and the nicotinic ACh receptors. As it is well established that muscarinic ACh receptors dominate quantitatively

nicotine/trötthet

Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (+)-bupropion

Methods and compositions for treating chronic disorders using optically pure (+)-bupropion

Pharmaceutically active morpholinol

2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof

2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof

2-halo-5-alkynyl-pyridyl nicotinic ligands

2-halo-5-alkynyl-pyridyl nicotinic ligands

Phenyl-substituted nicotinic ligands, and methods of use thereof

Phenyl-substituted nicotinic ligands, and methods of use thereof

Ligands for nicotinic acetylcholine receptors, and methods of making and using them

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen